Clinical trials: Lung Hypoplasia
Idiopathic Pulmonary Fibrosis
Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants
This is a phase I, First-in-Human study in healthy participants, performed at a single study center, consisting of 2 parts: Part 1 is a single ascending dose (SAD) study and Part 2 is a multiple ascending dose (MAD) study.
- Trial name
- NCT05134727
- Testing
- AZD5055
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non-Squamous Non-Small Cell Lung Cancer
Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants
The purpose of this non-interventional study is the collection and documentation of data on safety and efficacy of intravenous (IV) bevacizumab (Avastin) in addition to platinum-based chemotherapy for first-line treatment in…
- Trial name
- NCT02596958
- Testing
- Bevacizumab
- Where
- Germany
- Volunteers
- 996 people
- Sponsor
- Hoffmann-La Roche
Non-small Lung Cancer
Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
This is a multicenter, non-interventional, observational real-world study to evaluate the efficacy and safety of Taletrectinib in ROS1-positive non-small cell lung cancer (NSCLC) following Entrectinib progression.
- Trial name
- NCT07199010
- Testing
- Taletrectinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-small Cell Lung Cancer, Neoplasm Metastasis
ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Rationale: Overexpression of epidermal growth factor receptor (EGFR) has been observed in kidney, prostate, colon, lung, breast, and other cancers, and is often associated with a poor prognosis.
- Conditions
- Non-small Cell Lung Cancer, Neoplasm Metastasis, Lung Cancer
- Trial name
- NCT00101920
- Testing
- ABX-EGF
- Volunteers
- 50 people
- Sponsor
- Amgen
Pancreatic Ductal Adenocarcinoma (mPDAC), Unresectable Pancreatic Ductal Adenocarcinoma
Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC
An expanded access program (EAP) allows doctors to give medicine to seriously ill patients before it is approved by local regulatory agencies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (mPDAC), Unresectable Pancreatic Ductal Adenocarcinoma, Metastatic PDAC
- Trial name
- NCT07399015
- Testing
- mifomelatide
- Sponsor
- Endevica Bio
Metastatic Pancreatic Ductal Adenocarcinoma
Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
- Trial name
- NCT02558894
- Testing
- MEDI4736 monotherapy, tremelimumab+MEDI4736
- Where
- 21 sites in United States, Canada and 4 more
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC)…
- Conditions
- Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
- Trial name
- NCT05363280
- Testing
- AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped
- Where
- 7 sites in United States, Spain
- Volunteers
- 80 people
- Sponsor
- Advenchen Pharmaceuticals, LLC.
Breast Cancer, Non-small Lung Cancer
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
This is an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of oral GDC-0032 administered in combination with either docetaxel or with paclitaxel.
- Trial name
- NCT01862081
- Testing
- Docetaxel, GDC-0032, Paclitaxel
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 80 people
- Sponsor
- Genentech, Inc.
Lung Cancer, Breast Cancer
Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast Cancer
A multinational observational study to evaluate the current pathology practices and the utilization of computational pathology plus artificial intelligence algorithms in patients with suspected lung and breast cancer.
- Trial name
- CASCADE (NCT06827132)
- Where
- 2 sites in Brazil, Kenya
- Volunteers
- 603 people
- Sponsor
- AstraZeneca
Lung Cancer (Diagnosis)
Robotic Bronchoscopy for Small Lung Nodules Without a Bronchus Sign
The goal of this observational study is to learn about the diagnostic performance and safety of robotic-assisted bronchoscopy using the Ion Endoluminal System in adults with small lung nodules that do not show a bronchus sign on…
- Trial name
- NCT07862816
- Where
- 4 sites in South Korea
- Volunteers
- 151 people
- Sponsor
- Intuitive Surgical
Cancer
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
The purpose of this study is to determine the recommended dose and regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with everolimus in subjects with solid tumors.
- Trial name
- Cancer (NCT00955773)
- Testing
- GSK1120212 plus everolimus
- Where
- 3 sites in United States, France
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Multicystic Dysplastic Kidney, Polycystic Kidney Disease
Amnioinfusion for Fetal Renal Failure
The goal of this clinical trial is to learn if serial amnioinfusions can improve the chances of survival for fetuses with severe kidney problems that cause low amniotic fluid (anhydramnios).
- Conditions
- Multicystic Dysplastic Kidney, Polycystic Kidney Disease, Fetal Renal Anomaly, Anhydramnios
- Trial name
- NCT06728228
- Testing
- Amnioinfusion
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Fetal Care Center, PLLC
Non-Small Cell Lung Cancer, NSCLC
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
- Trial name
- NCT06917079
- Testing
- BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin)
- Where
- 17 sites in United States, Australia
- Volunteers
- 665 people
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Non-small Cell Lung Cancer
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.
- Trial name
- NCT02580708
- Testing
- Rociletinib, Trametinib
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Clovis Oncology, Inc.
Non-Small Cell Lung Cancer
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC
- Trial name
- NCT05054725
- Testing
- RMC-4630, Sotorasib
- Where
- 60 sites in United States, Australia and 8 more
- Volunteers
- 47 people
- Sponsor
- Revolution Medicines, Inc.
Non Small Cell Lung Cancer
Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer
The purpose of this study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa), in combination with pembrolizumab in patients with previously treated NSCLC.
- Trial name
- Acclaim-2 (NCT05062980)
- Testing
- quaratusugene ozeplasmid, pembrolizumab, docetaxel
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- Genprex, Inc.
Non-small Lung Cancer
A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
The aim of the study to evaluate the safety and efficacy of SKB571 for injection as monotherapy in patients with locally advanced or metastatic Non-Small Cell Lung Cancer with MET abnormalities.
- Trial name
- NCT07308106
- Testing
- SKB571 for injection
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer
This is a non-interventional, open label, single arm, multicenter study to assess the safety and efficacy of erlotinib in participants with non-small cell lung cancer.
- Trial name
- NCT02595450
- Testing
- Erlotinib
- Where
- Austria
- Volunteers
- 299 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer, Non-Small Cell
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The current standard treatment for this disease is radiation therapy to the brain.
- Trial name
- NCT00390806
- Testing
- HYCAMTIN, oral capsules, Radiation
- Where
- 88 sites in United States, Canada and 4 more
- Volunteers
- 472 people
- Sponsor
- GlaxoSmithKline
Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
- Trial name
- NCT06458712
- Testing
- DSB2455
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 180 people
- Sponsor
- Duke Street Bio Ltd